The HCV Revolution: Are You and Your Practice Ready?

Slides:



Advertisements
Similar presentations
Where Are We on the Path to Elimination of Chronic Hepatitis C?
Advertisements

Upfront Combination Therapy vs Step-Up Approach for PAH:
Chronic HCV Infection and CKD
Immunotherapies: Key Considerations in the Identification and Management of irAEs.
Diabetic Dyslipidemia in Practice
Evolution of Treatment Strategies Targeting IL-23 for Psoriasis
Chronic Hepatitis C Virus Infection
Why New Treatments for Schizophrenia Should Be on Your Radar
Unraveling Clinical Developments in NASH
Starting Strong: Initial Evaluation of the Patient With HCV
Advances in Managing Inhibitors in Patients With Hemophilia A
Updates on Emerging GLP-1 Receptor Agonists
Dual Antiretroviral Therapy
Applying New Data in Practice:
Progression After Cancer Immunotherapy in Advanced NSCLC
Induction Chemotherapy for Patients With High-Risk or Secondary AML
Examining CV Effects of Basal Insulin Therapy
Ending HCV: How Do We Get There From Here?
More Than Treatment.
The Resurgence of Topical Treatments Across a Spectrum of Psoriasis
Aligning Patients and Clinicians: Optimizing Outcomes in Metastatic NSCLC.
Emerging Targeted Agents for Relapsed/Refractory Non-Hodgkin Lymphoma
Addressing Disease Burden in Asthma
The Evolving Role of Immunotherapy in NSCLC
Optimizing Management of Advanced Bladder Cancer
Diagnostic and Management Challenges in Patients With Chronic Migraine
Next-Gen Psoriasis Therapies:
Management of CMV in HSCT Recipients
Evaluating Next-Generation BTK Inhibitors
Hyperhidrosis Is Burdensome!
Navigating New Oral Treatment Algorithms in CLL
Targeting BTK Signaling in B-Cell Malignancies
Essential Concepts in the Use of Immunotherapies in Bladder Cancer
Immunotherapy for cSCC
New Data on Emerging Treatments for Psoriasis
Personalizing Management in the Care of Patients With Advanced Sarcoma
This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.
Developments in the Wet AMD Treatment Landscape
Parkinson Disease Psychosis
Immune Checkpoint Inhibitors in Lung Cancer
Guide to Atopic Dermatitis
This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.
The Rising Cost of Healthcare and Potential Impact of Biosimilars
Moving the Goal Post: Multidisciplinary Management of Advanced NSCLC
Patient Questions and Expert Answers in Psoriasis:
A Guideline-Based Approach to HCV Care
Evaluating BTK Inhibitors in CLL
Managing CLL With BTK Inhibitors
This program will include a discussion of off-label treatment and investigational agents not approved by the Food and Drug Administration for use in the.
Novel Concepts in the Management of RCC
What Does the Future Hold and What Will It Mean for Patients?
This program will include a discussion of data that were presented in abstract form. These data should be considered preliminary until published in a.
Peanut Allergy Immunotherapy
From Adjuvant to Metastatic in Melanoma
The ABCs of Pharmacogenomics in Clinical Practice
Prioritizing Prevention of HPV-Related Disease
Case Studies in Locally Advanced Pancreatic Cancer
New Paradigms in M0 CRPC.
Peanut Allergy Immunotherapy
Optimizing Outcomes in mRCC: Finding the Balance of Immune Inhibition
This program will include a discussion of off-label treatment or use of investigational agents not approved by the FDA for use in the US, and data that.
Checkpoint Inhibitors in First-Line Advanced NSCLC
Peanut Allergy Immunotherapy
This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.
Pathophysiologic Targets of Allergic Asthma
Finding the Right Sequence in Patients With EGFR-Mutated NSCLC
MS, Age, and Immune Function
Immune Checkpoint Inhibitors in Lung Cancer
Comparative Studies of Biologics in Ulcerative Colitis
Meet the JAKs.
Presentation transcript:

The HCV Revolution: Are You and Your Practice Ready?

This program will include a discussion of data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

The Importance of Recognizing HCV

Treating Patients in the Interferon Era

The DAA Era -- Path to the Cure First Generation

The DAA Era -- Path to the Cure First Generation (cont)

The DAA Era -- Path to the Cure Second Generation

The DAA Era -- Path to the Cure Second Generation (cont)

The DAA Era -- Path to the Cure Third Generation

The DAA Era -- Path to the Cure Practical Considerations

Guidelines for Treatment of Chronic HCV Infection

HCV-TARGET

Efficacy of DAAs in Clinical Practice Clinical Trial Data vs Real-World Experience

Real-World Data Build Confidence

Caring for Patients in the Current Era The Opportunity Is Here, the Time Is Now

New HCV Infections Nearly Tripled Over 5 Years

Changing Demographics The "Second Bump"

Support Services for Effective Treatment Outcomes

Treating HCV in People Who Inject Drugs Debunking the Myths

Treating HCV in People Who Inject Drugs What Do the Data Show?

Treating People Who Inject Drugs Practical Realities

Some Patients Will Need to Be Referred

Get Started It’s Not Difficult, and It’s Very Rewarding

Practical Strategies for Making HCV Care a Part of Your Practice

Concluding Remarks

Abbreviations